- Home
- FLNT vs ACRV Comparison
FLNT vs ACRV Comparison
Compare FLNT & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLNT
- ACRV
- Stock Information
- Founded
- FLNT 2001
- ACRV 2018
- Country
- FLNT United States
- ACRV United States
- Employees
- FLNT N/A
- ACRV N/A
- Industry
- FLNT Advertising
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- FLNT Consumer Discretionary
- ACRV Health Care
- Exchange
- FLNT Nasdaq
- ACRV Nasdaq
- Market Cap
- FLNT 47.9M
- ACRV 40.4M
- IPO Year
- FLNT N/A
- ACRV 2022
- Fundamental
- Price
- FLNT $2.25
- ACRV $1.29
- Analyst Decision
- FLNT Hold
- ACRV Buy
- Analyst Count
- FLNT 1
- ACRV 7
- Target Price
- FLNT $3.00
- ACRV $17.60
- AVG Volume (30 Days)
- FLNT 22.2K
- ACRV 289.6K
- Earning Date
- FLNT 08-18-2025
- ACRV 08-12-2025
- Dividend Yield
- FLNT N/A
- ACRV N/A
- EPS Growth
- FLNT N/A
- ACRV N/A
- EPS
- FLNT N/A
- ACRV N/A
- Revenue
- FLNT $243,850,000.00
- ACRV N/A
- Revenue This Year
- FLNT N/A
- ACRV N/A
- Revenue Next Year
- FLNT $11.62
- ACRV N/A
- P/E Ratio
- FLNT N/A
- ACRV N/A
- Revenue Growth
- FLNT N/A
- ACRV N/A
- 52 Week Low
- FLNT $1.50
- ACRV $1.05
- 52 Week High
- FLNT $3.83
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- FLNT 50.39
- ACRV 45.62
- Support Level
- FLNT $2.17
- ACRV $1.28
- Resistance Level
- FLNT $2.48
- ACRV $1.48
- Average True Range (ATR)
- FLNT 0.28
- ACRV 0.10
- MACD
- FLNT -0.01
- ACRV -0.01
- Stochastic Oscillator
- FLNT 24.35
- ACRV 22.41
About FLNT Fluent Inc.
Fluent Inc is a data-driven digital marketing services company. It performs customer acquisition services by operating digital marketing campaigns, through which it connects its advertiser clients with consumers company is seeking to reach. It delivers data and performance-based marketing executions to its clients, such as consumer brands, direct marketers and agencies across a wide range of industries, including Financial Products & Services, Media & Entertainment, Health & Wellness, Staffing & Recruitment and Retail & Consumer.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.